Induction of tumor-reactive T helper responses by a posttranslational modified epitope from tumor protein p53

Takumi Kumai, Kei Ishibashi, Kensuke Oikawa, Yoshinari Matsuda, Naoko Aoki, Shoji Kimura, Satoshi Hayashi, Masahiro Kitada, Yasuaki Harabuchi, Esteban Celis, Hiroya Kobayashi

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Posttranslational modifications regulate the function and stability of proteins, and the immune system is able to recognize some of these modifications. Therefore, the presence of posttranslational modifications increases the diversity of potential immune responses to a determinant antigen. The stimulation of tumor-specific CD4+ helper T lymphocytes (HTLs) is considered important for the production of anti-tumor antibodies by B cells and for the generation and persistence of CD8+ cytotoxic T lymphocytes, and in some instances, HTLs can directly reduce tumor cell growth. Identification of MHC class II-restricted peptide epitopes from tumor-associated antigens including those generated from posttranslational protein modifications should enable the improvement of peptide-based cancer immunotherapy. We describe here an MHC class II binding peptide from the tumor protein p53, which possesses an acetylated lysine at position 120 (p53110-124/AcK120) that is effective in eliciting CD4+ T cell responses specific for the acetylated peptide. Most importantly, the acetylated peptide-reactive CD4 HTLs recognized the corresponding naturally processed posttranslational modified epitope presented by either dendritic cells loaded with tumor cell lysates or directly on tumors expressing p53 and the restricting MHC class II molecules. Treatment of tumor cells with a histone deacetylase inhibitor augmented their recognition by the p53110-124/AcK120-reactive CD4+ T cells. These findings prove that the epitope p53110-124/AcK120 is immunogenic for anti-tumor responses and is likely to be useful for cancer immunotherapy.

Original languageEnglish (US)
Pages (from-to)469-478
Number of pages10
JournalCancer Immunology, Immunotherapy
Volume63
Issue number5
DOIs
StatePublished - Jan 1 2014

Fingerprint

Epitopes
Neoplasms
Proteins
Post Translational Protein Processing
Peptides
Helper-Inducer T-Lymphocytes
Immunotherapy
Neoplasm Antibodies
T-Lymphocytes
Histone Deacetylase Inhibitors
Protein Stability
Cytotoxic T-Lymphocytes
Neoplasm Antigens
Dendritic Cells
Lysine
Anti-Idiotypic Antibodies
Immune System
B-Lymphocytes
Antigens
Growth

Keywords

  • Acetylated lysine
  • CD4 T cell
  • Epitope
  • Immunotherapy
  • Posttranslational modification
  • p53

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Immunology
  • Immunology and Allergy

Cite this

Induction of tumor-reactive T helper responses by a posttranslational modified epitope from tumor protein p53. / Kumai, Takumi; Ishibashi, Kei; Oikawa, Kensuke; Matsuda, Yoshinari; Aoki, Naoko; Kimura, Shoji; Hayashi, Satoshi; Kitada, Masahiro; Harabuchi, Yasuaki; Celis, Esteban; Kobayashi, Hiroya.

In: Cancer Immunology, Immunotherapy, Vol. 63, No. 5, 01.01.2014, p. 469-478.

Research output: Contribution to journalArticle

Kumai, T, Ishibashi, K, Oikawa, K, Matsuda, Y, Aoki, N, Kimura, S, Hayashi, S, Kitada, M, Harabuchi, Y, Celis, E & Kobayashi, H 2014, 'Induction of tumor-reactive T helper responses by a posttranslational modified epitope from tumor protein p53', Cancer Immunology, Immunotherapy, vol. 63, no. 5, pp. 469-478. https://doi.org/10.1007/s00262-014-1533-z
Kumai, Takumi ; Ishibashi, Kei ; Oikawa, Kensuke ; Matsuda, Yoshinari ; Aoki, Naoko ; Kimura, Shoji ; Hayashi, Satoshi ; Kitada, Masahiro ; Harabuchi, Yasuaki ; Celis, Esteban ; Kobayashi, Hiroya. / Induction of tumor-reactive T helper responses by a posttranslational modified epitope from tumor protein p53. In: Cancer Immunology, Immunotherapy. 2014 ; Vol. 63, No. 5. pp. 469-478.
@article{63d8c4e0c2624c3295ae7910ebce02c2,
title = "Induction of tumor-reactive T helper responses by a posttranslational modified epitope from tumor protein p53",
abstract = "Posttranslational modifications regulate the function and stability of proteins, and the immune system is able to recognize some of these modifications. Therefore, the presence of posttranslational modifications increases the diversity of potential immune responses to a determinant antigen. The stimulation of tumor-specific CD4+ helper T lymphocytes (HTLs) is considered important for the production of anti-tumor antibodies by B cells and for the generation and persistence of CD8+ cytotoxic T lymphocytes, and in some instances, HTLs can directly reduce tumor cell growth. Identification of MHC class II-restricted peptide epitopes from tumor-associated antigens including those generated from posttranslational protein modifications should enable the improvement of peptide-based cancer immunotherapy. We describe here an MHC class II binding peptide from the tumor protein p53, which possesses an acetylated lysine at position 120 (p53110-124/AcK120) that is effective in eliciting CD4+ T cell responses specific for the acetylated peptide. Most importantly, the acetylated peptide-reactive CD4 HTLs recognized the corresponding naturally processed posttranslational modified epitope presented by either dendritic cells loaded with tumor cell lysates or directly on tumors expressing p53 and the restricting MHC class II molecules. Treatment of tumor cells with a histone deacetylase inhibitor augmented their recognition by the p53110-124/AcK120-reactive CD4+ T cells. These findings prove that the epitope p53110-124/AcK120 is immunogenic for anti-tumor responses and is likely to be useful for cancer immunotherapy.",
keywords = "Acetylated lysine, CD4 T cell, Epitope, Immunotherapy, Posttranslational modification, p53",
author = "Takumi Kumai and Kei Ishibashi and Kensuke Oikawa and Yoshinari Matsuda and Naoko Aoki and Shoji Kimura and Satoshi Hayashi and Masahiro Kitada and Yasuaki Harabuchi and Esteban Celis and Hiroya Kobayashi",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s00262-014-1533-z",
language = "English (US)",
volume = "63",
pages = "469--478",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "5",

}

TY - JOUR

T1 - Induction of tumor-reactive T helper responses by a posttranslational modified epitope from tumor protein p53

AU - Kumai, Takumi

AU - Ishibashi, Kei

AU - Oikawa, Kensuke

AU - Matsuda, Yoshinari

AU - Aoki, Naoko

AU - Kimura, Shoji

AU - Hayashi, Satoshi

AU - Kitada, Masahiro

AU - Harabuchi, Yasuaki

AU - Celis, Esteban

AU - Kobayashi, Hiroya

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Posttranslational modifications regulate the function and stability of proteins, and the immune system is able to recognize some of these modifications. Therefore, the presence of posttranslational modifications increases the diversity of potential immune responses to a determinant antigen. The stimulation of tumor-specific CD4+ helper T lymphocytes (HTLs) is considered important for the production of anti-tumor antibodies by B cells and for the generation and persistence of CD8+ cytotoxic T lymphocytes, and in some instances, HTLs can directly reduce tumor cell growth. Identification of MHC class II-restricted peptide epitopes from tumor-associated antigens including those generated from posttranslational protein modifications should enable the improvement of peptide-based cancer immunotherapy. We describe here an MHC class II binding peptide from the tumor protein p53, which possesses an acetylated lysine at position 120 (p53110-124/AcK120) that is effective in eliciting CD4+ T cell responses specific for the acetylated peptide. Most importantly, the acetylated peptide-reactive CD4 HTLs recognized the corresponding naturally processed posttranslational modified epitope presented by either dendritic cells loaded with tumor cell lysates or directly on tumors expressing p53 and the restricting MHC class II molecules. Treatment of tumor cells with a histone deacetylase inhibitor augmented their recognition by the p53110-124/AcK120-reactive CD4+ T cells. These findings prove that the epitope p53110-124/AcK120 is immunogenic for anti-tumor responses and is likely to be useful for cancer immunotherapy.

AB - Posttranslational modifications regulate the function and stability of proteins, and the immune system is able to recognize some of these modifications. Therefore, the presence of posttranslational modifications increases the diversity of potential immune responses to a determinant antigen. The stimulation of tumor-specific CD4+ helper T lymphocytes (HTLs) is considered important for the production of anti-tumor antibodies by B cells and for the generation and persistence of CD8+ cytotoxic T lymphocytes, and in some instances, HTLs can directly reduce tumor cell growth. Identification of MHC class II-restricted peptide epitopes from tumor-associated antigens including those generated from posttranslational protein modifications should enable the improvement of peptide-based cancer immunotherapy. We describe here an MHC class II binding peptide from the tumor protein p53, which possesses an acetylated lysine at position 120 (p53110-124/AcK120) that is effective in eliciting CD4+ T cell responses specific for the acetylated peptide. Most importantly, the acetylated peptide-reactive CD4 HTLs recognized the corresponding naturally processed posttranslational modified epitope presented by either dendritic cells loaded with tumor cell lysates or directly on tumors expressing p53 and the restricting MHC class II molecules. Treatment of tumor cells with a histone deacetylase inhibitor augmented their recognition by the p53110-124/AcK120-reactive CD4+ T cells. These findings prove that the epitope p53110-124/AcK120 is immunogenic for anti-tumor responses and is likely to be useful for cancer immunotherapy.

KW - Acetylated lysine

KW - CD4 T cell

KW - Epitope

KW - Immunotherapy

KW - Posttranslational modification

KW - p53

UR - http://www.scopus.com/inward/record.url?scp=84899975289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899975289&partnerID=8YFLogxK

U2 - 10.1007/s00262-014-1533-z

DO - 10.1007/s00262-014-1533-z

M3 - Article

VL - 63

SP - 469

EP - 478

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 5

ER -